T-cell cellular stress and reticulocyte signatures, but not loss of naïve T lymphocytes, characterize severe COVID-19 in older adults
Geroscience submission-final_c ...
Final Accepted Manuscript
Coplen, Christopher P
Sonar, Sandip A
Wilson, Rachel C
Twigg, Homer L
Erickson, Heidi E
Weinkauf, Craig C
Bixby, Billie A
Mosier, Jarrod M
LaFleur, Bonnie J
Nikolich, Janko Z
AffiliationDepartment of Immunobiology, University of Arizona College of Medicine-Tucson
Arizona Center on Aging, University of Arizona College of Medicine-Tucson
Department of Medicine, University of Arizona College of Medicine-Phoenix
Division of Vascular Surgery, University of Arizona
Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, University of Arizona College of Medicine Tucson
Department of Emergency Medicine, University of Arizona College of Medicine Tucson
BIO5 Institute, University of Arizona
R. Ken Coit College of Pharmacy, University of Arizona
MetadataShow full item record
CitationJergović, M., Watanabe, M., Bhat, R., Coplen, C. P., Sonar, S. A., Wong, R., Castaneda, Y., Davidson, L., Kala, M., Wilson, R. C., Twigg, H. L., III, Knox, K., Erickson, H. E., Weinkauf, C. C., Bime, C., Bixby, B. A., Parthasarathy, S., Mosier, J. M., LaFleur, B. J., … Nikolich, J. Z. (2023). T-cell cellular stress and reticulocyte signatures, but not loss of naïve T lymphocytes, characterize severe COVID-19 in older adults. GeroScience.
Rights© 2023. The Author(s), under exclusive licence to American Aging Association.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractIn children and younger adults up to 39 years of age, SARS-CoV-2 usually elicits mild symptoms that resemble the common cold. Disease severity increases with age starting at 30 and reaches astounding mortality rates that are ~330 fold higher in persons above 85 years of age compared to those 18–39 years old. To understand age-specific immune pathobiology of COVID-19, we have analyzed soluble mediators, cellular phenotypes, and transcriptome from over 80 COVID-19 patients of varying ages and disease severity, carefully controlling for age as a variable. We found that reticulocyte numbers and peripheral blood transcriptional signatures robustly correlated with disease severity. By contrast, decreased numbers and proportion of naïve T-cells, reported previously as a COVID-19 severity risk factor, were found to be general features of aging and not of COVID-19 severity, as they readily occurred in older participants experiencing only mild or no disease at all. Single-cell transcriptional signatures across age and severity groups showed that severe but not moderate/mild COVID-19 causes cell stress response in different T-cell populations, and some of that stress was unique to old severe participants, suggesting that in severe disease of older adults, these defenders of the organism may be disabled from performing immune protection. These findings shed new light on interactions between age and disease severity in COVID-19.
NoteNo embargo COVID-19
VersionFinal accepted manuscript
- T-cell cellular stress and reticulocyte signatures, but not loss of naïve T lymphocytes, characterize severe COVID-19 in older adults.
- Authors: Jergović M, Watanabe M, Bhat R, Coplen CP, Sonar SA, Wong R, Castaneda Y, Davidson L, Kala M, Wilson RC, Twigg HL 3rd, Knox K, Erickson HE, Weinkauf CC, Bime C, Bixby BA, Parthasarathy S, Mosier JM, LaFleur BJ, Bhattacharya D, Nikolich JŽ
- Issue date: 2022 Dec 22
- Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
- Authors: Demaret J, Corroyer-Simovic B, Alidjinou EK, Goffard A, Trauet J, Miczek S, Vuotto F, Dendooven A, Huvent-Grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Labreuche J, Sobaszek A, Hisbergues M, Puisieux F, Labalette M, Lefèvre G
- Issue date: 2021
- Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns.
- Authors: Christensen EE, Jørgensen MJ, Nore KG, Dahl TB, Yang K, Ranheim T, Huse C, Lind A, Nur S, Stiksrud B, Jenum S, Tonby K, Holter JC, Holten AR, Halvorsen B, Dyrhol-Riise AM
- Issue date: 2021 Sep
- Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients.
- Authors: Hou Y, Zhou Y, Jehi L, Luo Y, Gack MU, Chan TA, Yu H, Eng C, Pieper AA, Cheng F
- Issue date: 2022 Feb
- The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
- Authors: Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R
- Issue date: 2020 Jun 8